

Hui Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1816790/publications.pdf>

Version: 2024-02-01

59
papers

1,355
citations

394421

19
h-index

377865

34
g-index

63
all docs

63
docs citations

63
times ranked

2336
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide CRISPR/Cas9 screening identifies determinant of panobinostat sensitivity in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 2496-2509.	5.2	7
2	Dasatinib therapy induced sustained remission in a child with refractory <i>TCF7</i> <i>SPI1</i> <i>T</i> cell acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29724.	1.5	4
3	Stress and Perception of Procedural Pain Management in Chinese Parents of Children With Cancer. <i>Journal of Pain and Symptom Management</i> , 2021, 61, 90-102.e5.	1.2	6
4	<i>GATA3</i> rs3824662A allele in <i>B</i> cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with <i>CRLF2</i> rearrangement and poor prognosis. <i>American Journal of Hematology</i> , 2021, 96, E71-E74.	4.1	5
5	Effects of <i>NT5C2</i> Germline Variants on 6-Mercaptopurine Metabolism in Children With Acute Lymphoblastic Leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1538-1545.	4.7	5
6	Association of <i>GATA3</i> Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2021, 113, 408-417.	6.3	16
7	Identifying Priorities for Harmonizing Guidelines for the Long-Term Surveillance of Childhood Cancer Survivors in the Chinese Children Cancer Group (CCCCG). <i>JCO Global Oncology</i> , 2021, 7, 261-276.	1.8	14
8	Association Between <i>NR3C1</i> Mutations and Glucocorticoid Resistance in Children With Acute Lymphoblastic Leukemia. <i>Frontiers in Pharmacology</i> , 2021, 12, 634956.	3.5	6
9	Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation. <i>Blood</i> , 2021, 138, 331-343.	1.4	46
10	Single-Cell RNA-seq Reveals Characteristics of Malignant Cells and Immune Microenvironment in Subcutaneous Panniculitis-Like T-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 611580.	2.8	7
11	Anti- <i>CLL1</i> Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 3549-3555.	7.0	51
12	Clinical characteristics of tumor lysis syndrome in childhood acute lymphoblastic leukemia. <i>Scientific Reports</i> , 2021, 11, 9656.	3.3	6
13	Toward the Cure of Acute Lymphoblastic Leukemia in Children in China. <i>JCO Global Oncology</i> , 2021, 7, 1176-1186.	1.8	4
14	Inherited <i>GATA3</i> variant associated with positive minimal residual disease in childhood <i>B</i> cell acute lymphoblastic leukemia via asparaginase resistance. <i>Clinical and Translational Medicine</i> , 2021, 11, e507.	4.0	0
15	Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , 2021, 22, 1322-1332.	10.7	42
16	Functional Outcomes and Social Attainment in Asian/Pacific Islander Childhood Cancer Survivors in the United States: A Report from the Childhood Cancer Survivor Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2244-2255.	2.5	4
17	Delayed Diagnosis of Langerhans Cell Histiocytosis Presenting With Thyroid Involvement and Respiratory Failure: A Pediatric Case Report. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e810-e812.	0.6	4
18	<i>ARID5B</i> Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 256-264.	7.0	25

#	ARTICLE	IF	CITATIONS
19	Down-Regulated FOXO1 in Refractory/Relapse Childhood B-Cell Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 579673.	2.8	3
20	FPGS relapse-specific mutations in relapsed childhood acute lymphoblastic leukemia. <i>Scientific Reports</i> , 2020, 10, 12074.	3.3	6
21	Chemosensitization by 4-hydroxyphenyl retinamide-induced NF- κ B inhibition in acute myeloid leukemia cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 257-266.	2.3	3
22	4-Hydroxyphenyl Retinamide Preferentially Targets FLT3 Mutated Acute Myeloid Leukemia via ROS Induction and NF- κ B Inhibition. <i>Current Medical Science</i> , 2020, 40, 810-816.	1.8	3
23	Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 685.	2.8	29
24	Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2020, 6, 358.	7.1	159
25	Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia. <i>Blood</i> , 2020, 136, 1161-1168.	1.4	9
26	Clinical ascertainment of health outcomes in Asian survivors of childhood cancer: a systematic review. <i>Journal of Cancer Survivorship</i> , 2019, 13, 374-396.	2.9	28
27	A cis-element within the ARF locus mediates repression of p16 ^{INK4A} expression via long-range chromatin interactions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 26644-26652.	7.1	16
28	Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. <i>Blood</i> , 2019, 133, 724-729.	1.4	44
29	Association of the GATA3 rs3824662A allele with clinical outcomes in adult patients with adult B-ALL. <i>Journal of Clinical Oncology</i> , 2019, 37, 7023-7023.	1.6	1
30	Effect of Dasatinib Vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized, Open-Label, Multicenter Study of the Chinese Children's Cancer Group. <i>Blood</i> , 2019, 134, 828-828.	1.4	0
31	Inherited GATA3 Variants Associated with Positive Minimal Residual Disease in Childhood B-ALL Via Autophagy-Induced Asparaginase Resistance. <i>Blood</i> , 2019, 134, 654-654.	1.4	0
32	Lack of Benefit of Extended Vincristine and Dexamethasone Pulses during Maintenance Treatment of Childhood Acute Lymphoblastic Leukemia: A Multicenter Randomized Controlled Study of Chinese Children Cancer Group (CCCC)-ALL-2015. <i>Blood</i> , 2019, 134, 2576-2576.	1.4	0
33	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2018, 33, 937-948.e8.	16.8	142
34	PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. <i>Blood</i> , 2018, 131, 2256-2261.	1.4	49
35	TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. <i>Journal of Clinical Oncology</i> , 2018, 36, 591-599.	1.6	121
36	PML \rightarrow RAR \rightarrow interferes with erythropoiesis by repressing LMO2 in acute promyelocytic leukaemia. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 6275-6284.	3.6	3

#	ARTICLE	IF	CITATIONS
37	Leukemia Risk Gene ARID5B is a Crucial Regulator of B-Cell Development. <i>Blood</i> , 2018, 132, 385-385.	1.4	2
38	Multi-Dimensional Humanistic Care for the Kids with Hematological Malignancies in Guangzhou Women and Children's Medical Center (GWCMC). <i>Blood</i> , 2018, 132, 3560-3560.	1.4	1
39	Inherited NUDT15 Variants Substantially Increased Infection and Related Medical Cost in Children with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 320-320.	1.4	1
40	Novel MEIS1-FOXO1 Fusion Gene in a Case of Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 5283-5283.	1.4	0
41	The Impact of Pain Control on Invasive Clinical Procedure on Children with Leukemia. <i>Blood</i> , 2018, 132, 5827-5827.	1.4	0
42	Mutational Landscape and Temporal Evolution during Treatment of Relapsed Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 917-917.	1.4	0
43	The Efficacy and Safety of Super High-Dose Cytarabine Based Strategies in Childhood Acute Myeloid Leukemia Treatment. <i>Blood</i> , 2018, 132, 5178-5178.	1.4	0
44	Whole-genome noncoding sequence analysis in T-cell acute lymphoblastic leukemia identifies oncogene enhancer mutations. <i>Blood</i> , 2017, 129, 3264-3268.	1.4	32
45	Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of <i>EP300</i> and <i>CREBBP</i> . <i>Genome Research</i> , 2017, 27, 185-195.	5.5	105
46	Regulatory network of <i>GATA3</i> in pediatric acute lymphoblastic leukemia. <i>Oncotarget</i> , 2017, 8, 36040-36053.	1.8	30
47	Abstract 3005: Whole-genome sequencing identified novel non-coding mutations causal of oncogene activation in T-cell acute lymphoblastic leukemia. , 2017, , .		0
48	Abstract 4870: Mutational landscape and timing of resistant clone emergence in 104 Chinese pediatric patients with relapsed acute lymphoblastic leukemia. , 2017, , .		0
49	Germline Genetic Variation in IKZF1 and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, LBA-2-LBA-2.	1.4	3
50	Whole Transcriptome Sequencing Identified a Distinct Subtype of Acute Lymphoblastic Leukemia with Abnormalities of CREBBP and EP300. <i>Blood</i> , 2016, 128, 3912-3912.	1.4	0
51	Chemosensitizing Effect of Fenretinide-Induced NF- κ B Inhibition in AML Therapy. <i>Blood</i> , 2016, 128, 1580-1580.	1.4	0
52	PML-Rara Drives Acute Promyelocytic Leukemia Genesis By Enhanceosome Depletion Leading to 3D Chromatin Reorganization. <i>Blood</i> , 2016, 128, 1554-1554.	1.4	0
53	Dehydroxymethylepoxyquinomicin selectively ablates T-CAEBV cells. <i>Frontiers in Bioscience - Landmark</i> , 2015, 20, 502-514.	3.0	3
54	Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. <i>Nature Genetics</i> , 2015, 47, 263-266.	21.4	109

#	ARTICLE	IF	CITATIONS
55	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. <i>Nature Communications</i> , 2015, 6, 7553.	12.8	72
56	Reactive oxygen species in eradicating acute myeloid leukemic stem cells. <i>Stem Cell Investigation</i> , 2014, 1, 13.	3.0	20
57	Preferential eradication of acute myelogenous leukemia stem cells by fenretinide. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 5606-5611.	7.1	49
58	The significance of low PU.1 expression in patients with acute promyelocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2012, 5, 22.	17.0	20
59	Converting Redox Signaling to Apoptotic Activities by Stress-Responsive Regulators HSF1 and NRF2 in Fenretinide Treated Cancer Cells. <i>PLoS ONE</i> , 2009, 4, e7538.	2.5	34